Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study

Study (n=355) found the objective response rate, overall survival and progression-free survival was higher with ipilimumab plus anti-PD-1 vs ipilimumab monotherapy; 31% vs 13% (p<0·0001), 20.4 vs 8.8months; (p<0·0001) and 3.0 vs 2.6 months (p=0·0019), respectively.

The Lancet Oncology